About 60 percent of the population is heading into the winter months with reduced protection against the coronavirus, CDC data shows.
The MHRA has granted marketing authorisation for diroximel fumarate as oral treatment for relapsing-remitting multiple sclerosis.
An AI-based diagnostic tool is being developed through a biotech startup.
We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.